Ocular Therapeutix (OCUL) to Release Earnings on Monday

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 5th. Analysts expect Ocular Therapeutix to post earnings of ($0.28) per share and revenue of $17.02 million for the quarter.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last issued its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The firm had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. On average, analysts expect Ocular Therapeutix to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Ocular Therapeutix Stock Performance

NASDAQ OCUL traded up $0.27 during trading hours on Friday, hitting $8.80. The company had a trading volume of 1,558,376 shares, compared to its average volume of 1,436,686. The company has a market cap of $1.40 billion, a PE ratio of -6.67 and a beta of 1.51. Ocular Therapeutix has a 1-year low of $4.79 and a 1-year high of $11.78. The business has a 50 day moving average of $7.40 and a 200-day moving average of $8.39. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $15.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a research report on Tuesday, March 4th. William Blair initiated coverage on shares of Ocular Therapeutix in a research note on Tuesday, April 8th. They set an "outperform" rating on the stock. Royal Bank of Canada assumed coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price objective for the company. Finally, Needham & Company LLC restated a "buy" rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Ocular Therapeutix currently has a consensus rating of "Moderate Buy" and a consensus price target of $16.38.

Insider Transactions at Ocular Therapeutix

In related news, insider Donald Notman sold 11,119 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the transaction, the insider now owns 193,444 shares in the company, valued at $1,510,797.64. This trade represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Pravin Dugel sold 21,475 shares of the company's stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the sale, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. This trade represents a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by company insiders.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.